Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models

Journal of Clinical Investigation

Volumn 125, Issue 1, 2015, Pages 350-364

  Johansson, Jenny U ^a,d   Woodling, Nathaniel S ^a,b,e   Wang, Qian ^a   Panchal, Maharshi ^a   Liang, Xibin ^a   Trueba Saiz, Angel ^c   Brown, Holden D ^a,f   Mhatre, Siddhita D ^a   Loui, Taylor ^a   Andreasson, Katrin I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c INSTITUTO CAJAL   (Spain)

^d SRI INTERNATIONAL   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BUTAPROST; CD68 ANTIGEN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INOSINATE DEHYDROGENASE; INSULINASE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIGOMER; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; RANTES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SYNAPTOPHYSIN; AMYLOID BETA-PROTEIN (1-42); CHEMOKINE; PEPTIDE FRAGMENT; TRANSCRIPTOME;

ADULT; AGED; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CORTEX; CELL DAMAGE; CELL FUNCTION; CELL MIGRATION; CELL PROTECTION; CELL SURVIVAL; CHEMOTAXIS; COGNITION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENOTYPE; HOMEOSTASIS; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MEMORY CONSOLIDATION; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; OXIDATIVE STRESS; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECOGNITION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SPATIAL MEMORY; SYNAPTOGENESIS; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; HIPPOCAMPUS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPTOSOME; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELLS, CULTURED; CHEMOKINES; CHEMOTAXIS; DINOPROSTONE; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROGLIA; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESYNAPTIC TERMINALS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SIGNAL TRANSDUCTION; SPATIAL MEMORY; TRANSCRIPTOME;

EID: 84920405563     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77487     Document Type: Article

References (72)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119-1122.
2. Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795-804.
3. Jack CR, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-216.
4. Sperling RA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
5. Naj AC, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet. 2011;43(5):436-441.
6. Bertram L, et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623-632.
7. Hollingworth P, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43(5):429-435.
8. Guerreiro R, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013;368(2):117-127.
9. Jonsson T, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013;368(2):107-116.
10. Lambert JC, et al. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013;45(12):1452-1458.
11. Lambert JC, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41(10):1094-1099.
12. Raj T, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344(6183):519-523.
13. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci. 2008;28(33):8354-8360.
14. Krabbe G, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PLoS One. 2013;8(4):e60921.
15. in t' Veld BA, et al. Nonsteroidal antiinflamma-tory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345(21):1515-1521.
16. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48(3):626-632.
17. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70(19):1672-1677.
18. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47(2):425-432.
19. Montine TJ, et al. Elevated cerebrospinal fluid prostaglandin E2 levels in patients with probable Alzheimer's disease. Neurology. 1998;53(7):1495-1498.
20. Combrinck M, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77(1):85-88.
21. Shi J, et al. Inflammatory prostaglandin E(2) signaling in a mouse model of Alzheimer disease. Ann Neurol. 2012;72(5):788-798.
22. Liang X, et al. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci. 2005;25(44):10180-10187.
23. Zhen G, et al. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease. Neurobiol Aging. 2012;33(9):2215-2219.
24. Keene CD, et al. Suppressed accumulation of cerebral amyloid {beta} peptides in aged trans-genic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Am J Pathol. 2010;177(1):346-354.
25. Shie FS, Montine KS, Breyer RM, Montine TJ. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol. 2005;15(2):134-138.
26. Johansson JU, et al. Suppression of inflammation with conditional deletion of the prostaglandin E2 EP2 receptor in macrophages and brain micro-glia. J Neurosci. 2013;33(40):16012-16032.
27. Mucke L, Selkoe DJ. Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7):a006338.
28. Woodling NS, et al. Suppression of Alzheimer-associated inflammation by microglial prosta-glandin-E2 EP4 receptor signaling. J Neurosci. 2014;34(17):5882-5894.
29. Shi J, Johansson J, Woodling NS, Wang Q, Mon-tine TJ, Andreasson K. The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol. 2010;184(12):7207-7218.
30. Savonenko A, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neuro-biol Dis. 2005;18(3):602-617.
31. Boillee S, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science. 2006;312(5778):1389-1392.
32. Morris GP, Clark IA, Zinn R, Vissel B. Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem. 2013;105:40-53.
33. Figueiredo CP, et al. Memantine rescues transient cognitive impairment caused by high-molecular-weight abeta oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci. 2013;33(23): 9626-9634.
34. Heneka MT, Landreth GE, Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-y in CNS disorders. Nat Clin Pract Neurol. 2007;3(9):496-504.
35. Yamanaka M, Ishikawa T, Griep A, Axt D, Kummer MP, Heneka MT. PPARy/RXRa-induced and CD36-mediated microglial amyloid-ß phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci. 2012;32(48):17321-17331.
36. Chawla A, et al. A PPARy-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7(1):161-171.
37. Laffitte BA, et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;98(2) 507-512.
38. Jiang Q, et al. ApoE promotes the proteolytic degradation of Aß. Neuron. 2008;58(5):681-693.
39. Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-y-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci. 2012;32(30):10117-10128.
40. Cramer PE, et al. ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075):1503-1506.
41. Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on "ApoE-directed therapeutics rapidly clear ß-amyloid and reverse deficits in AD mouse models". Science. 2013;340(6135):924-c.
42. Han J, Sridevi P, Ramirez M, Ludwig KJ, Wang JY. ß-Catenin-dependent lysosomal targeting of internalized tumor necrosis factor-a suppresses caspase-8 activation in apoptosis-resistant colon cancer cells. Mol Biol Cell. 2013;24(4):465-473.
43. Fontana L, Partridge L, Longo VD. Extending healthy life span - from yeast to humans. Science. 2010;328(5976):321-326.
44. Fernandez AM, Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci. 2012;13(4):225-239.
45. Ueno M, et al. Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci. 2013;16(5):543-551.
46. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(8):933-944.
47. Sanchez-Varo R, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol. 2012;123(1):53-70.
48. Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurds-son EM. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol. 2011;122(3):285-292.
49. Fiala M, et al. Ineffective phagocytosis of amyloid-β by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2005;7(3):221-232.
50. Mawuenyega KG, et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science. 2010;330(6012):1774.
51. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-κB activity. Genes Dev. 2007;21(24):3244-3257.
52. Landreth GE, et al. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science. 2013;340(6135):924-g.
53. McNamara P, Seo SB, Rudic RD, Sehgal A, Chakra-varti D, FitzGerald GA. Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vascu-lature: a humoral mechanism to reset a peripheral clock. Cell. 2001;105(7):877-889.
54. Musiek ES, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegenera-tion. J Clin Invest. 2013;123(12):5389-5400.
55. Kondratova AA, Kondratov RV. The circadian clock and pathology of the ageing brain. Nat Rev Neurosci. 2012;13(5):325-335.
56. Peek CB, et al. Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice. Science. 2013;342(6158):1243417.
57. Talbot K, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dys-regulation, and cognitive decline. J Clin Invest. 2012;122(4):1316-1338.
58. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-β levels. Nat Med. 2002;8(12):1390-1397.
59. Dziennis S, et al. The CD11b promoter directs high-level expression of reporter genes in macrophages in transgenic mice. Blood. 1995;85(2):319-329.
60. Ferron M, Vacher J. Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. Genesis. 2005;41(3):138-145.
61. Villeda SA, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477(7362):90-94.
62. Villeda SA, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. 2014;20(6):659-663.
63. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17(6):157-165.
64. Breyer RM, Kennedy CR, Zhang Y, Guan Y, Breyer MD. Targeted gene disruption of the prostaglandin E2 EP2 receptor. Adv Exp Med Biol. 2002;507:321-326.
65. Kennedy CR, et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999;5(2):217-220.
66. Yang T, et al. Small molecule, non-peptide p75 ligands inhibit Aβ-induced neurodegen-eration and synaptic impairment. PLoS One. 2008;3(11):e3604.
67. El Khoury J, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med. 2007;13(4):432-438.
68. El Khoury JB, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197(12):1657-1666.
69. Piermartiri TC, et al. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp Neurol. 2010;226(2):274-284.
70. Melnikova T, et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience. 2006;141(3):1149-1162.
71. Dere E, Huston JP, De Souza Silva MA. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev. 2007;31(5):673-704.
72. Clelland CD, et al. A functional role for adult hip-pocampal neurogenesis in spatial pattern separation. Science. 2009;325(5937):210-213.